Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER vs AMINOSOL 5%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Travasol 4.25% in Dextrose 15% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The mechanism involves intravenous administration bypassing the gastrointestinal tract to deliver nutrients directly into the bloodstream, supporting tissue repair, growth, and metabolic functions.
Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.
Parenteral nutrition for patients unable to obtain adequate nutrition orally or enterally,Adjunct to oral or enteral nutrition when intake is insufficient,Metabolic support in catabolic states such as major surgery, trauma, or burns
Total parenteral nutrition in patients with inadequate oral or enteral intake,Correction of negative nitrogen balance in malnourished patients
Intravenous infusion; typical adult dose is 500 m L to 1000 m L per day, administered at a rate of 200 m L/hour, adjusted based on metabolic and fluid needs.
Intravenous infusion: 500 m L to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.
Not applicable as a single entity; components have intrinsic half-lives. Amino acids: rapid distribution (minutes), with terminal elimination of metabolites (e.g., urea) ~4-8 hours. Dextrose: half-life ~1-2 hours in steady state.
The half-life of infused amino acids is not defined as they are endogenous compounds. However, the nitrogen from amino acids has a biological half-life of approximately 6-18 hours, depending on metabolic activity. As part of total parenteral nutrition, the elimination half-life of infused amino acids is influenced by protein turnover and catabolism.
The amino acids in Travasol are metabolized via various pathways including transamination, deamination, and urea cycle in the liver and other tissues. Dextrose undergoes glycolysis and oxidative phosphorylation to produce ATP.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Excretion of nitrogenous waste as urea occurs renally.
TRAVASOL 4.25% IN DEXTROSE 15% (amino acids and dextrose) is a parenteral nutrition solution. Amino acids are metabolized to urea, which is excreted renally; dextrose is metabolized to CO2 and water. No significant biliary/fecal elimination.
Excretion of infused amino acids is primarily renal, with small amounts lost via feces and skin. Approximately 85-95% of the nitrogen load is excreted in urine as urea, ammonia, and other nitrogenous wastes. Less than 5% is eliminated in feces.
Amino acids: minimal to no protein binding (<10%). Dextrose: not protein bound.
Amino acids are not protein-bound; they exist free in plasma. Minimal reversible binding to albumin occurs for some amino acids, but overall binding is <10%.
Total body water distribution: ~0.55 L/kg for amino acids; dextrose distributes in extracellular fluid (~0.2 L/kg).
The volume of distribution for amino acids is approximately 0.3-0.4 L/kg, reflecting distribution primarily in extracellular fluid and to a lesser extent intracellularly.
IV: 100% bioavailability; not administered orally or via other routes.
Intravenous: 100% bioavailability. Not administered via other routes; oral or enteral administration is not applicable due to hepatic first-pass metabolism and different pharmacokinetics.
In acute kidney injury or chronic kidney disease with GFR <30 m L/min, reduce volume and rate; monitor for electrolyte imbalances; consider avoidance in severe renal impairment.
In GFR < 50 m L/min: reduce infusion rate by 50% and monitor nitrogen balance. In ESRD on dialysis: use only if essential; typical dose 0.5-0.6 g/kg/day of amino acids with careful monitoring.
No specific Child-Pugh based adjustments; use with caution in severe hepatic encephalopathy; monitor ammonia levels.
Contraindicated in severe hepatic failure (Child-Pugh C) due to risk of hepatic encephalopathy. In Child-Pugh A or B, use with caution and reduce dose by 30-50%; monitor ammonia levels.
Dose based on weight: 2 to 6 g/kg/day of amino acids and 15 g/kg/day of dextrose; start at 2 g/kg/day of amino acids and titrate; typical infusion rate 100-200 m L/kg/day.
Infants and children: 1-2 g/kg/day of amino acids via total parenteral nutrition (TPN) as a 5% solution. Adjust based on age, weight, and clinical condition. Maximum infusion rate 0.1 g/kg/hour.
Start at lower infusion rates (e.g., 100 m L/hour); monitor fluid balance, renal function, and electrolytes; reduce total volume to avoid fluid overload.
Start at lower end of dosing; monitor renal function (creatinine clearance) and avoid fluid overload. Typical initial dose: 0.8-1 g/kg/day of amino acids, adjusted to tolerance and clinical response.
None
None.
Do not administer if solution is discolored or contains particulate matter,Use with caution in patients with renal impairment, hepatic failure, or metabolic disorders,Monitor fluid and electrolyte balance, blood glucose, and acid-base status,Risk of infections related to catheter use,Rebound hypoglycemia may occur upon abrupt discontinuation
Use with caution in patients with renal impairment (risk of azotemia and electrolyte imbalances),Monitor serum electrolytes, blood glucose, and fluid balance regularly,Risk of hyperglycemia in diabetic patients; adjust insulin accordingly,Possible hyperammonemia, especially in patients with hepatic insufficiency,Contains aluminum; may accumulate in renal impairment, leading to osteomalacia or neurotoxicity
Hypersensitivity to any component,Inborn errors of amino acid metabolism,Severe hyperglycemia or hyperosmolar state,Severe electrolyte disturbances,Severe hepatic or renal failure
Severe hepatic failure with encephalopathy,Severe uremia without dialysis,Inborn errors of amino acid metabolism,Hypersensitivity to any component
No oral intake restrictions specific to this formulation as it is for parenteral use. However, if transitioning to oral feeding, coordinate with dietitian to avoid electrolyte imbalances or overfeeding.
No direct food interactions as Aminos 5% is administered intravenously. However, oral dietary intake must be coordinated with total parenteral nutrition to avoid excessive protein or electrolyte intake.
No expected increase in fetal malformation risk; amino acids and dextrose are endogenous nutrients. However, electrolyte disturbances or hyperglycemia may occur and can affect fetal development. First trimester: theoretical risk from metabolic derangements. Second and third trimesters: fetal growth and metabolic monitoring recommended.
Aminosol 5% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with Aminosol 5%. Therefore, the teratogenic risk is not well defined. However, as a component of parenteral nutrition, it is considered essential for maternal and fetal health when indicated. Use only if clearly needed, weighing potential benefits against unknown risks. No specific trimester-associated risks have been reported.
Components are normal blood constituents and are transferred into breast milk in small amounts. Not expected to cause adverse effects in breastfed infants. M/P ratio not established.
Aminosolic 5% is a mixture of amino acids naturally present in human milk. Administration to lactating women may result in excretion of amino acids into breast milk, but the amounts are unlikely to be clinically significant. The M/P ratio is not known. Caution is advised, but use is generally considered compatible with breastfeeding when clinically indicated.
Increased plasma volume and renal clearance in pregnancy may necessitate higher infusion rates to maintain adequate nutrition; individualize based on clinical response and laboratory parameters.
Standard adult dosing (5% solution, 500-1000 m L/day) may be used; however, increased fluid volume and metabolic demands in pregnancy may require dose adjustments. Monitor for fluid overload and adjust infusion rate accordingly. No specific dose adjustment recommendations are established; use caution and individualize based on clinical status.
TRAVASOL 4.25% IN DEXTROSE 15% is a high-osmolarity parenteral nutrition solution (approximately 1700 m Osm/L). Must be administered via central venous line to avoid thrombophlebitis. Monitor serum glucose, electrolytes, renal function, and liver enzymes frequently. Risk of hyperglycemia, especially in stressed patients; consider insulin coverage. Do not use as a peripheral line solution due to high osmolarity.
Aminos 5% is a crystalline amino acid solution used for parenteral nutrition. In renal failure, adjust dose to limit nitrogen load; monitor BUN. In hepatic encephalopathy, consider branched-chain amino acid formulations. Do not administer concurrently with blood products through same IV line due to risk of agglutination. Infuse via central line if peripheral veins insufficient; peripheral administration requires adequate lipid-based calorie co-administration to prevent phlebitis.
This solution is given through a large vein in your chest, not a small vein in your arm.,You may need regular blood tests to check your blood sugar, kidney function, and mineral levels.,Report any signs of infection at the catheter site, such as redness, swelling, or pain.,Tell your healthcare provider if you feel unusually thirsty, urinate frequently, or have blurred vision.,Do not stop the infusion suddenly without medical advice.
This solution provides essential building blocks (amino acids) for protein synthesis when you cannot eat.,Report any signs of infection at the IV site: redness, swelling, pain, or drainage.,Tell your doctor if you experience nausea, vomiting, or headache; dose adjustment may be needed.,Do not abruptly stop this infusion; it is part of your total nutrition plan.,Regular blood tests will be required to monitor kidney and liver function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER vs AMINOSOL 5%, answered by our medical review team.
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Travasol 4.25% in Dextrose 15% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The mechanism involves intravenous administration bypassing the gastrointestinal tract to deliver nutrients directly into the bloodstream, supporting tissue repair, growth, and metabolic functions.. AMINOSOL 5% is a Parenteral Nutrition Solution that works by Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER and AMINOSOL 5% depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 500 m L to 1000 m L per day, administered at a rate of 200 m L/hour, adjusted based on metabolic and fluid needs.. The standard adult dose of AMINOSOL 5% is: Intravenous infusion: 500 m L to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER and AMINOSOL 5% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER is classified as Category C. No expected increase in fetal malformation risk; amino acids and dextrose are endogenous nutrients. However, electrolyte disturbances or hyperglycemia may occur and can affect feta. AMINOSOL 5% is classified as Category C. Aminosol 5% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies hav. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.